Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
复制标题
DOI：
10.1177/0269881116675513
复制
发表时间：
2016-12
期刊：
影响因子：
--
通讯作者：
Klinedinst MA
中科院分区：
文献类型：
--
作者：
Griffiths RR;Johnson MW;Carducci MA;Umbricht A;Richards WA;Richards BD;Cosimano MP;Klinedinst MA
癌症患者通常会出现慢性的、临床上显著的抑郁和焦虑症状。以前的研究表明，裸盖菇素可能会减少癌症患者的抑郁和焦虑。在51名患有危及生命的诊断和抑郁和/或焦虑症状的癌症患者中研究了裸盖菇素的作用。这项随机、双盲、交叉试验研究了极低（安慰剂样）剂量（1或3 mg/70 kg）与高剂量（22或30 mg/70 kg）的裸盖菇素以平衡顺序给药的效果，疗程间隔5周，随访6个月。对参与者和工作人员的指示最大限度地减少了预期效应。参与者、工作人员和社区观察员在整个研究过程中对参与者的情绪、态度和行为进行评分。高剂量的裸盖菇素使临床医生和自我评定的抑郁情绪和焦虑程度大幅下降，沿着生活质量、生活意义和乐观情绪的提高，死亡焦虑的降低。在6个月的随访中，这些变化持续存在，约80%的参与者继续表现出抑郁情绪和焦虑的临床显著下降。参与者将对生活/自我，情绪，关系和精神的态度的改善归因于高剂量的体验，>80%的人赞同适度或更大程度的幸福感/生活满意度增加。社区观察员的评分也出现了相应的变化。治疗当天的神秘型裸盖菇素体验介导了裸盖菇素剂量对治疗结果的影响。 试用注册ClinicalTrials.gov标识符：NCT 00465595
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the effects of a very low (placebo-like) dose (1 or 3 mg/70 kg) vs. a high dose (22 or 30 mg/70 kg) of psilocybin administered in counterbalanced sequence with 5 weeks between sessions and a 6-month follow-up. Instructions to participants and staff minimized expectancy effects. Participants, staff, and community observers rated participant moods, attitudes, and behaviors throughout the study. High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety. Participants attributed improvements in attitudes about life/self, mood, relationships, and spirituality to the high-dose experience, with >80% endorsing moderately or greater increased well-being/life satisfaction. Community observer ratings showed corresponding changes. Mystical-type psilocybin experience on session day mediated the effect of psilocybin dose on therapeutic outcomes. Trial Registration ClinicalTrials.gov identifier: NCT00465595